Press Releases

Date Title and Summary View
Toggle Summary Zosano Announces Closing of Public Offering of Common Stock
FREMONT, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the closing of the previously
View HTML
Toggle Summary Zosano Pharma to Host Conference Call to Provide Operational Update
FREMONT, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today
View HTML
Toggle Summary Zosano Announces Pricing of Public Offering of Common Stock
FREMONT, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the pricing of an
View HTML
Toggle Summary Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study
103 patients have enrolled in study
View HTML
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update
First patient enrolled in long term safety study in November 2017 Pivotal efficacy data for M207 published in October 2017 Allowed patent application to be issued in March 2018 extends proprietary position for M207 to 2037 FREMONT, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma
View HTML
Toggle Summary Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine
Patent extends proprietary position of M207 to 2037
View HTML
Toggle Summary Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split
Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on January 26, 2018
View HTML
Toggle Summary Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine
Issuance Will Extend Patent Life of M207 to 2037
View HTML
Toggle Summary Zosano Announces Resignation of Bruce Steel from Board of Directors
FREMONT, Calif., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today
View HTML
Toggle Summary Zosano Pharma to Present at 29th Annual Piper Jaffray Healthcare Conference
FREMONT, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML